Hope for Parkinson's Patients as Serina Trial Begins

HUNTSVILLE, AL – February 19, 2026 – Serina Therapeutics announced today that the first patient has been enrolled in a pivotal clinical trial for SER-252, a novel investigational therapy for advanced Parkinson's disease. The milestone, achieved in Australia, marks a critical step forward for a treatment designed to overcome significant limitations of current therapies and improve the quality of life for patients battling the debilitating neurological condition.

The Challenge of Advanced Parkinson's

Parkinson's disease, a progressive neurodegenerative disorder, affects millions worldwide. While initial symptoms can often be managed with medications like levodopa, which replenishes the brain's supply of dopamine, the advanced stages of the disease present a formidable challenge for both patients and clinicians.

Over time, the effectiveness of levodopa can wane, leading to debilitating motor fluctuations. Patients often experience "off" periods, where their medication stops working and symptoms like tremors, stiffness, and slow movement return with a vengeance. Conversely, they can also suffer from dyskinesia—uncontrollable, jerky movements that are a direct side effect of the long-term medication. This creates a precarious balancing act, forcing patients to navigate a narrow therapeutic window between immobility and involuntary motion.

To address this, continuous delivery systems have been developed, most notably using apomorphine, a potent dopamine agonist. These therapies aim to provide a steady level of medication, smoothing out the peaks and valleys that cause motor complications. However, existing apomorphine infusions often require patients to wear a pump and insert a needle under their skin daily, a process that is not only burdensome but frequently leads to painful skin nodules and reactions at the injection site, causing many to abandon the treatment. This leaves a significant unmet need for a therapy that can provide continuous dopaminergic stimulation without the associated drawbacks.

A New Delivery System, A New Promise

Serina Therapeutics believes its candidate, SER-252, offers a solution. The therapy utilizes the company's proprietary POZ Platform™, a sophisticated drug delivery technology designed to optimize existing medications. The platform is based on a synthetic polymer called poly(2-oxazoline), or POZ, which acts as a scaffold for the drug molecule—in this case, apomorphine.

This POZ-apomorphine conjugate is engineered for slow, continuous release following a subcutaneous injection. The goal is to provide the steady, therapeutic drug levels needed to reduce "off" time and dyskinesia, but with a dosing schedule that could be as infrequent as once or twice weekly. Crucially, preclinical studies suggest that the POZ platform may allow for this continuous stimulation without causing the skin reactions that plague current apomorphine pumps.

"Enrolling our first patient represents an important operational milestone as we advance SER-252 into the clinic," said Steve Ledger, Chief Executive Officer of Serina Therapeutics, in a statement. "Our team has built a strong operational presence in Australia, working closely with leading Parkinson's disease specialists and patient advocacy organizations to support efficient enrollment."

The Phase 1b trial is designed to rigorously evaluate the safety, tolerability, and pharmacokinetics of SER-252, while also gathering preliminary data on its effectiveness in patients whose symptoms are not adequately controlled by standard care.

A Strategic Path to Market

Serina's approach is not just scientific but also highly strategic. The company is pursuing a 505(b)(2) New Drug Application (NDA) pathway with the U.S. Food and Drug Administration (FDA). This streamlined regulatory route allows a company to reference safety and efficacy data from a previously approved drug—in this case, apomorphine—dramatically reducing the time, cost, and risk associated with drug development. Instead of a decade or more, this pathway can shorten the journey to market to as little as three to eight years.

The decision to initiate the global registrational study in Australia is another key part of this strategy. Australia has become a premier destination for early-stage clinical trials due to its efficient regulatory process, which can allow studies to begin in a matter of weeks, and its attractive R&D tax incentives that can provide rebates of up to 43.5% on research costs. By partnering with local organizations like Parkinson's Australia and Neuroscience Trials Australia, Serina is leveraging an established infrastructure to accelerate patient recruitment.

This combination of an innovative delivery platform, a well-understood therapeutic agent, and a savvy regulatory and operational plan has positioned Serina to potentially bring a much-needed new option to patients more quickly.

Navigating a Competitive Landscape

Serina enters a dynamic and competitive field. Other companies are also vying to improve the delivery of dopamine-related therapies. AbbVie markets the Vyalev pump, a continuous under-the-skin infusion of a levodopa/carbidopa solution, while NeuroDerm is developing a similar system. Just last year, the FDA approved Onapgo, another continuous apomorphine infusion, creating a direct competitor.

SER-252's potential success will hinge on its ability to differentiate itself. If the clinical trial confirms that it can provide the benefits of continuous dopaminergenic stimulation with a more convenient dosing schedule and, most importantly, a significantly improved skin safety profile, it could carve out a major niche in the market. While this therapy focuses on symptom management, it represents a vital effort to improve daily life for those with advanced Parkinson's, as other researchers continue the longer-term search for disease-modifying drugs that could slow or halt the progression of the disease itself.

The enrollment of the first patient is just the beginning of a long clinical journey. The data generated from this Phase 1b trial will be scrutinized by researchers, investors, and regulatory bodies. For the thousands of individuals living with the daily struggles of advanced Parkinson's disease, however, it represents a tangible step forward and a new reason for hope.